Portzamparc Initiates Coverage of Crossject with a 'Buy' Recommendation
Portzamparc, a subsidiary of BNP Paribas, has initiated coverage of Crossject stock with a 'Buy' recommendation and a target price of €4.50. This coverage adds to the four other analysts already following the specialized pharmaceutical company.
Portzamparc (BNP Paribas Group) has launched coverage of Crossject stock with a report titled 'The Needle Will Soon Be a Bad Memory'. According to the analyst's note, the recommendation is 'Buy' with a target price set at €4.50. Crossject is developing ZEPIZURE®, an injectable for managing epilepsy seizures, based on its proprietary needle-free auto-injector technology, ZENEO®. The company has secured a $60 million contract from the BARDA (Administration for Strategic Preparedness and Response) of the U.S. Department of Health.
Analytical Coverage Expansion
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Crossject is now followed by five analysts: Alpha Value, Invest Securities, Maxim Group, Oddo, and Portzamparc. The specialized pharmaceutical company is also developing other products for emergency situations, including treatments for allergic shocks, adrenal insufficiency, opioid overdoses, and asthma attacks.
Related
SectorÉquipements et Services Médicaux›Équipements Médicaux
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
